China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for chronic obstructive pulmonary ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK's Nucala gets China approval for chronic rhinosinusitis with nasal polyps; awaits FDA decision for COPD in May as it ...

Mepolizumab is currently approved under the brand name Nucala for maintenance treatment of severe asthma with an eosinophilic phenotype and chronic rhinosinusitis with nasal polyps, as well as for ...

The submission seeks an indication for the use of Nucala as an add-on maintenance treatment for patients with COPD with an eosinophilic phenotype. The Prescription Drug User Fee Act (PDUFA ...

Nucala has been developed for the treatment of a range of IL-5 mediated diseases associated with type 2 inflammation. About the mepolizumab development programme for COPD The mepolizumab program ...

Nucala is already approved in the US for four IL-5-mediated conditions, including severe asthma and chronic rhinosinusitis with nasal polyps, but is not currently indicated for COPD treatment ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD ...